{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T12:58:59Z","timestamp":1682600339538},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bioinform Sys Biology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1687-4153-2012-19","type":"journal-article","created":{"date-parts":[[2012,12,26]],"date-time":"2012-12-26T17:14:17Z","timestamp":1356542057000},"source":"Crossref","is-referenced-by-count":5,"title":["Dynamical modeling of drug effect using hybrid systems"],"prefix":"10.1186","volume":"2012","author":[{"given":"Xiangfang","family":"Li","sequence":"first","affiliation":[]},{"given":"Lijun","family":"Qian","sequence":"additional","affiliation":[]},{"given":"Edward R","family":"Dougherty","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2012,12,26]]},"reference":[{"key":"29_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1359-6446(02)02463-7","volume":"7","author":"S Huang","year":"2002","unstructured":"Huang S: Rational drug discovery: what can we learn from regulatory networks. Drug Discov. Today 2002, 7: 163-169. 10.1016\/S1359-6446(02)02463-7","journal-title":"Drug Discov. Today"},{"key":"29_CR2","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/nbt1017","volume":"22","author":"E Butcher","year":"2004","unstructured":"Butcher E, Berg E, Kunkel E: System biology in drug discovery. Nat. Biotechnol 2004, 22: 1253-1259. 10.1038\/nbt1017","journal-title":"Nat. Biotechnol"},{"key":"29_CR3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.drudis.2006.07.010","volume":"11","author":"N Kumar","year":"2006","unstructured":"Kumar N, Hendriks B, Janes K, Graaf D, Lauffenburger D: Applying computational modeling to drug discovery and development. Drug Discov. Today 2006, 11: 806-811. 10.1016\/j.drudis.2006.07.010","journal-title":"Drug Discov. Today"},{"issue":"2","key":"29_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1109\/MCAS.2005.1438739","volume":"5","author":"J Chen","year":"2005","unstructured":"Chen J, Dougherty E, Demir S, Friedman C, Li C, Wong S: Grand challenges for multimodal bio-medical systems. IEEE Circuits Syst. Mag 2005, 5(2):46-52.","journal-title":"IEEE Circuits Syst. Mag"},{"issue":"2","key":"29_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1023\/A:1011907920641","volume":"16","author":"H Derendorf","year":"1999","unstructured":"Derendorf H, Meibohm B: Modeling of pharmacokinetic\/pharmacodynamic (PK\/PD) relationships: concepts and perspectives. Pharm. Res 1999, 16(2):176-185. 10.1023\/A:1011907920641","journal-title":"Pharm. Res"},{"key":"29_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/0-387-33706-7","volume-title":"Dose Finding in Drug Development","author":"N Ting","year":"2006","unstructured":"Ting N: Introduction and new drug development process. In Dose Finding in Drug Development. Edited by: Ting N. New York: Springer; 2006."},{"key":"29_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc1629","volume":"5","author":"S Undevia","year":"2005","unstructured":"Undevia S, Gomez-Abuin G, Ratain M: Pharmacokinetic variability of anticancer agents. Nat. Rev. Cancer 2005, 5: 447-458. 10.1038\/nrc1629","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"29_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","volume":"14","author":"N Shah","year":"2008","unstructured":"Shah N, Kasap C, Weier C, Balbas M, Nicoll J, Bleickardt E, Nicaise C, Sawyers C: Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer cell 2008, 14(6):485-493. 10.1016\/j.ccr.2008.11.001","journal-title":"Cancer cell"},{"issue":"16","key":"29_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.3000389","volume":"2","author":"D Amin","year":"2010","unstructured":"Amin D, Sergina N, Ahuja D, McMahon M, Blair J, Wang D, Hann B, Koch K, Shokat K, Moasser M: Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci. Transl. Med 2010, 2(16):1-9.","journal-title":"Sci. Transl. Med"},{"key":"29_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cbpa.2005.06.008","volume":"9","author":"P Rajasethupathy","year":"2005","unstructured":"Rajasethupathy P, Vayttaden S, Bhalla U: Systems modeling: a pathway to drug discovery. Curr. Opin. Chem. Biol 2005, 9: 400-406. 10.1016\/j.cbpa.2005.06.008","journal-title":"Curr. Opin. Chem. Biol"},{"key":"29_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nrd1754","volume":"4","author":"E Butcher","year":"2005","unstructured":"Butcher E: Can cell systems biology rescue drug discovery? Nat. Rev. Drug Discov 2005, 4: 461-467. 10.1038\/nrd1754","journal-title":"Nat. Rev. Drug Discov"},{"issue":"6","key":"29_CR12","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1186\/1471-2164-13-S6-S11","volume":"13","author":"X Li","year":"2012","unstructured":"Li X, Qian L, Hua J, Bittner M, Dougherty E: Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification. BMC Genomics 2012, 13(6):S11.","journal-title":"BMC Genomics"},{"key":"29_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1109\/TCBB.2007.70247","volume":"6","author":"E Dougherty","year":"2009","unstructured":"Dougherty E, Brun M, Trent J, Bittner M: Conditioning-based modeling of contextual genomic regulation. IEEE\/ACM Trans. Comput. Biol. Bioinf 2009, 6: 310-320.","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinf"},{"key":"29_CR14","doi-asserted-by":"publisher","first-page":"13670","DOI":"10.1073\/pnas.95.23.13670","volume":"95","author":"A Kringstein","year":"1998","unstructured":"Kringstein A, Rossi F, Hofmann A, Blau H: Graded transcriptional response to different concentrations of a single transactivator. Proc. Natl Acad. Sci. USA 1998, 95: 13670-13675. 10.1073\/pnas.95.23.13670","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"Suppl 1","key":"29_CR15","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1098\/rsif.2008.0086.focus","volume":"5","author":"M Santillan","year":"2008","unstructured":"Santillan M, Mackey M: Quantitative approaches to the study of bistability in the lac operon of Escherichia coli. J. R. Soc. Interface 2008, 5(Suppl 1):S29-S39.","journal-title":"J. R. Soc. Interface"},{"key":"29_CR16","doi-asserted-by":"publisher","DOI":"10.1515\/9783110879476","volume-title":"The Lac Operon: A Short History of a Genetic Paradigm","author":"B Muller-Hill","year":"1996","unstructured":"Muller-Hill B: The Lac Operon: A Short History of a Genetic Paradigm. New York: Walter de Gruyter; 1996."},{"key":"29_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1049\/iet-syb:20060035","volume":"1","author":"A Halasz","year":"2007","unstructured":"Halasz A, Kumar V, Imielinski M, Belta C, Sokolsky O, Pathak S, Rubin H: Analysis of lactose metabolism in E. coli using reachability analysis of hybrid systems. IET Syst. Biol 2007, 1: 120-148. 10.1049\/iet-syb:20050098","journal-title":"IET Syst. Biol"},{"key":"29_CR18","first-page":"233","volume":"LNCS 2623","author":"R Ghosh","year":"2003","unstructured":"Ghosh R, Tiwari A, Tomlin C: Automated symtolic reachability analysis; with application to delta-notch signaling automata. Hybrid Syst.: Comput. Control 2003, LNCS 2623: 233-248.","journal-title":"Hybrid Syst.: Comput. Control"},{"key":"29_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1049\/sb:20045019","volume":"1","author":"R Ghosh","year":"2004","unstructured":"Ghosh R, Tomlin C: Symbolic reachable set computation of piecewise affine hybrid automata and its application to biological modelling: delta-notch protein signalling. IET Syst. Biol 2004, 1: 170-183. 10.1049\/sb:20045019","journal-title":"IET Syst. Biol"},{"key":"29_CR20","first-page":"184","volume":"LNCS 3927","author":"S Drulhe","year":"2006","unstructured":"Drulhe S, Ferrari-Trecate G, de Jone H, Viari A: Reconstruction of switching thresholds in piecewise-affine models of genetic regulatory networks. Hybrid Syst.: Comput. Control 2006, LNCS 3927: 184-199.","journal-title":"Hybrid Syst.: Comput. Control"},{"key":"29_CR21","first-page":"134","volume":"LNCS 3414","author":"G Batt","year":"2005","unstructured":"Batt G, Ropers D, de Jone H, Geiselmann J, Page M, Schneider D: Qualitative analysis and verification of hybrid models of genetic regulatory networks: nutritional stress response in Escherichia coli. Hybrid Syst.: Comput. Control 2005, LNCS 3414: 134-150.","journal-title":"Hybrid Syst.: Comput. Control"},{"issue":"3","key":"29_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1109\/TBME.2010.2090660","volume":"58","author":"X Li","year":"2011","unstructured":"Li X, Qian L, Bittner M, Dougherty E: Characterization of drug efficacy regions based on dosage and frequency schedules. IEEE Trans. Biomed. Eng 2011, 58(3):488-498.","journal-title":"IEEE Trans. Biomed. Eng"},{"key":"29_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/10665270252833208","volume":"9","author":"H de Jong","year":"2002","unstructured":"de Jong H: Modeling and simulation of genetic regulatory systems: a literature review. J. Comput. Biol 2002, 9: 67-103. 10.1089\/10665270252833208","journal-title":"J. Comput. Biol"},{"key":"29_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0022-5193(73)90208-7","volume":"39","author":"L Glass","year":"1973","unstructured":"Glass L, Kauffman S: The logical analysis of continuous non-linear biochemical control networks. J. Theor. Biol 1973, 39: 103-129. 10.1016\/0022-5193(73)90208-7","journal-title":"J. Theor. Biol"},{"issue":"6","key":"29_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0188-4409(00)00242-3","volume":"31","author":"J Prez-Urizar","year":"2000","unstructured":"Prez-Urizar J, Granados-Soto V, Flores-Murrieta FJ, Castada-Hernndez G: Pharmacokinetic\u2013pharmacodynamic modeling: why? Arch. Med. Res 2000, 31(6):539-545. 10.1016\/S0188-4409(00)00242-3","journal-title":"Arch. Med. Res"},{"key":"29_CR26","first-page":"iv","volume":"40","author":"AV Hill","year":"1910","unstructured":"Hill AV: The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol 1910, 40: iv-vii.","journal-title":"J. Physiol"},{"issue":"6","key":"29_CR27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-198106060-00002","volume":"6","author":"NH Holford","year":"1981","unstructured":"Holford NH, Sheiner LB: Understanding the dose\u2013effect relationship: clinical application of pharmacokinetic\u2013pharmacodynamic models. Clin. Pharmacokinet 1981, 6(6):429-453. 10.2165\/00003088-198106060-00002","journal-title":"Clin. Pharmacokinet"},{"key":"29_CR28","first-page":"13","volume":"177","author":"DR Waud","year":"1971","unstructured":"Waud DR, Parker RB: Pharmacological estimation of drug\u2013receptor dissociation constants. Statistical evaluation. II. Competitive antagonists. J. Pharmacol. Exp. Ther 1971, 177: 13-24.","journal-title":"J. Pharmacol. Exp. Ther"},{"issue":"3","key":"29_CR29","first-page":"761","volume":"293","author":"H Kuh","year":"2000","unstructured":"Kuh H, Jang S, Wientjes M, Au J: Computational model of intracellular pharmacokinetics of paclitaxel. J. Pharmacol. Exp. Ther 2000, 293(3):761-770.","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"29_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1042\/BJ20060756","volume":"402","author":"AR Tzafriri","year":"2007","unstructured":"Tzafriri AR, Edelman ER: Endosomal receptor kinetics determine the stability of intracellular growth factor signalling complexes. Biochem. J 2007, 402: 537-549. 10.1042\/BJ20060756","journal-title":"Biochem. J"},{"key":"29_CR31","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrd2378","volume":"6","author":"J Kramer","year":"2007","unstructured":"Kramer J, Sagartz J, Morris D: The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discov 2007, 6: 636-649. 10.1038\/nrd2378","journal-title":"Nat. Rev. Drug Discov"},{"issue":"2","key":"29_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1172\/JCI11914","volume":"107","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto Y, Gaynor R: Therapeutic potential of inhibition of the NF-\u03baB pathway in the treatment of inflammation and cancer. J. Clin. Invest 2001, 107(2):135-142. 10.1172\/JCI11914","journal-title":"J. Clin. Invest"},{"key":"29_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud V, Karin M: Is NF-\u03baB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov 2009, 8: 33-40. 10.1038\/nrd2781","journal-title":"Nat. Rev. Drug Discov"},{"issue":"8","key":"29_CR34","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1126\/science.1071914","volume":"298","author":"A Hoffmann","year":"2002","unstructured":"Hoffmann A, Levchenko A, Scott ML, Baltimore D: The IkBNF-kB signaling module: temporal control and selective gene activation. Science 2002, 298(8):1241-1245.","journal-title":"Science"},{"key":"29_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1124\/mol.66.1.70","volume":"66","author":"M Sung","year":"2004","unstructured":"Sung M, Simon R: In silico simulation of inhibitor drug effects on nuclear factor-kB pathway dynamics. Mol. Pharmacol 2004, 66: 70-75. 10.1124\/mol.66.1.70","journal-title":"Mol. Pharmacol"},{"issue":"6","key":"29_CR36","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","volume":"14","author":"R Orlowski","year":"2008","unstructured":"Orlowski R, Kuhn D: Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res 2008, 14(6):1649-1657. 10.1158\/1078-0432.CCR-07-2218","journal-title":"Clin. Cancer Res"}],"container-title":["EURASIP Journal on Bioinformatics and Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1687-4153-2012-19\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1687-4153-2012-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1687-4153-2012-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T11:49:48Z","timestamp":1595159388000},"score":1,"resource":{"primary":{"URL":"https:\/\/bsb-eurasipjournals.springeropen.com\/articles\/10.1186\/1687-4153-2012-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["29"],"URL":"https:\/\/doi.org\/10.1186\/1687-4153-2012-19","relation":{},"ISSN":["1687-4153"],"issn-type":[{"value":"1687-4153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]},"article-number":"19"}}